US Broker Ratings

Immunocore Holdings plc (IMCR) Stock Analysis: A Biotech with a 93% Potential Upside

Immunocore Holdings plc (NASDAQ: IMCR), a UK-based biotechnology firm, is garnering significant attention from investors due to its promising portfolio of immunotherapies and an impressive potential upside of 93.03%. Specializing..

Opko Health, Inc. (OPK) Stock Analysis: Exploring a 162% Potential Upside Amidst Market Challenges

Opko Health, Inc. (NASDAQ: OPK) is a prominent player within the healthcare sector, specifically in the diagnostics and research industry. With a market capitalization of $1.1 billion, Opko Health operates..

U.S. Physical Therapy, Inc. (USPH) Stock Analysis: Uncovering a 28.89% Potential Upside

U.S. Physical Therapy, Inc. (NYSE: USPH), a prominent player in the healthcare sector, has attracted significant investor interest due to its promising growth metrics and robust market presence. Specializing in..

89bio, Inc. (ETNB) Stock Analysis: Exploring a 232% Potential Upside in Biotechnology

89bio, Inc. (NASDAQ: ETNB) is making waves in the biotechnology sector with its promising pipeline and compelling financial metrics. This clinical-stage biopharmaceutical company, headquartered in San Francisco, is focused on..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech with a 169% Upside Potential

Apogee Therapeutics, Inc. (APGE) is capturing the attention of the biotechnology investment community with its promising pipeline and potential for significant stock appreciation. As a clinical-stage biotech company, Apogee focuses..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Harnessing a Potential 166% Upside with Innovative Allergy Solutions

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is captivating investor attention with its innovative approach in the biotechnology space, specifically targeting the treatment of severe allergic reactions. Operating within the healthcare sector,..

Investor Outlook: Arcutis Biotherapeutics (ARQT) Poised for 40% Upside Potential Amid Strong Analyst Consensus

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a promising player in the biotechnology sector, is making waves with its focused approach to developing innovative treatments for dermatological diseases. With a market capitalization..

Arrowhead Pharmaceuticals (ARWR): Analyst Consensus and 98.75% Upside Potential

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a prominent player in the biotechnology sector, has captured investor interest with a compelling growth narrative and a promising pipeline of advanced therapeutic candidates. With..

Biohaven Ltd. (BHVN) Stock Analysis: Unveiling a 206.32% Potential Upside in the Biotech Sector

Biohaven Ltd. (BHVN), a burgeoning player in the biotechnology sector, is capturing investor attention with its ambitious pipeline and impressive analyst ratings. With a market capitalization of $1.63 billion, Biohaven..

HUTCHMED (China) Limited (HCM) Stock Analysis: Navigating a 52% Potential Upside Amidst Healthcare Innovations

HUTCHMED (China) Limited (NASDAQ: HCM), a prominent player in the healthcare sector specializing in the development of targeted therapeutics and immunotherapies, offers a compelling case for investors interested in the..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Exploring a 35.19% Upside Potential in the Biotech Arena

PTC Therapeutics, Inc. (NASDAQ: PTCT) is a compelling player in the biotechnology sector, offering significant upside potential for investors willing to navigate the complexities of the biopharmaceutical landscape. As a..

PACS Group, Inc. (PACS) Stock Analysis: Exploring a Potential 162% Upside in the Healthcare Sector

PACS Group, Inc. (PACS), a notable player in the healthcare sector, is currently capturing the attention of investors with its substantial potential upside. Operating primarily in the medical care facilities..

Schrodinger, Inc. (SDGR) Stock Analysis: Exploring a 39.93% Potential Upside with Strong Buy Ratings

Schrodinger, Inc. (SDGR) stands out in the healthcare sector as a pioneer in health information services, leveraging cutting-edge technology to advance molecular discovery. Headquartered in New York, this innovative company..

BioLife Solutions, Inc. (BLFS) Stock Analysis: A 24.95% Upside Potential in the Booming Healthcare Sector

BioLife Solutions, Inc. (NASDAQ: BLFS) is an intriguing player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $1.2 billion, BioLife is..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Exploring an 89.99% Upside Potential

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is capturing investor attention with its promising pipeline of pharmaceutical innovations and substantial upside potential. As a prominent player in the biotechnology sector, Centessa operates..

Artivion, Inc. (AORT) Stock Analysis: Navigating Growth in Medical Devices with a 15.3% Revenue Surge

Artivion, Inc. (NASDAQ: AORT) stands out as a robust player within the healthcare sector, specifically in the medical devices industry. Known for its innovative contributions to cardiac and vascular medical..

Neogen Corporation (NEOG) Stock Analysis: Navigating Challenges with a 13% Potential Upside

Neogen Corporation (NASDAQ: NEOG), a notable player in the healthcare sector, specifically within the diagnostics and research industry, continues to capture investor attention despite facing significant financial hurdles. Headquartered in..

NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Marvel with a 68.70% Upside Potential

NewAmsterdam Pharma Company N.V. (NAMS) is capturing the attention of investors with its promising growth trajectory in the biotechnology sector. Based in Naarden, Netherlands, this late-stage biopharmaceutical company is making..

Progyny, Inc. (PGNY) Stock Analysis: Evaluating a 19.35% Potential Upside in Healthcare Innovation

Progyny, Inc. (NASDAQ: PGNY), a pioneering company in the healthcare sector, specializes in offering comprehensive fertility and family-building benefits. With a market capitalization of $2.04 billion, Progyny’s innovative approach positions..

MannKind Corporation (MNKD): Investor Outlook with Over 100% Potential Upside

MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company with a market cap of $1.41 billion, has been making waves in the biotechnology sector, particularly in the development of therapeutic products for..

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds